Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at EUR 71.85 EUR in weekly data.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 71.76 support.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company is one of the best yield companies with high dividend expectations.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The group usually releases earnings worse than estimated.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • Analysts covering the stock have recently lowered their earnings forecast.
  • The underlying tendency is negative on the weekly chart below the resistance at 81.37 EUR
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
SANOFI0.72%112 074
JOHNSON & JOHNSON5.20%394 704
NOVARTIS0.61%224 711
PFIZER2.65%220 487
ROCHE HOLDING LTD.-5.40%210 743
MERCK AND COMPANY10.24%166 723
AMGEN8.11%136 174
NOVO NORDISK A/S2.24%110 515
BAYER-0.50%104 914
ABBOTT LABORATORIES3.36%102 817
BRISTOL-MYERS SQUIBB COMPAN..0.93%101 197
ELI LILLY AND COMPANY0.98%94 496
GLAXOSMITHKLINE2.32%93 292
ASTRAZENECA-2.74%87 603
CELGENE CORPORATION-2.24%80 086
ALLERGAN PLC8.03%59 745
More Results
Financials (€)
Sales 2017 35 761 M
EBIT 2017 9 145 M
Net income 2017 7 967 M
Debt 2017 5 749 M
Yield 2017 4,18%
P/E ratio 2017 11,45
P/E ratio 2018 15,93
EV / Sales 2017 2,72x
EV / Sales 2018 2,67x
Capitalization 91 413 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart SANOFI
Duration : Period : Day
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Duration : Period : Week
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders